Literature DB >> 19275881

Effect of atorvastatin on expression of IL-10 and TNF-alpha mRNA in myocardial ischemia-reperfusion injury in rats.

Yan-Ming Sun1, Ye Tian, Xiang Li, Yuan-Yuan Liu, Lan-Feng Wang, Jia Li, Zhu-Qin Li, Wei Pan.   

Abstract

Myocardial ischemia and reperfusion (MI/R) is associated with an intense inflammatory reaction, which may lead to myocyte injury. Because statins protect the myocardium against ischemia-reperfusion injury via a mechanism unrelated to cholesterol lowering, we hypothesized that the protective effect of statins was related to the expression of TNF-alpha (TNF-alpha) and interleukin-10 (IL-10) mRNA. Seventy-two rats were randomly divided into three groups as follows: sham, I/R and I/R+atorvastatin. Atorvastatin (20 mg kg(-1)day(-1)) treatment was administered daily via oral gavage to rats for 2, 7 or 14 days. Ischemia was induced via a 30-min coronary occlusion. Reperfusion was allowed until 2, 7 or 14 days while atorvastatin treatment continued. We measured infarct size, hemodynamics and the plasma levels and the mRNA expression of TNF-alpha and IL-10 in the three groups. We demonstrated that the up-regulation of expression of both TNF-alpha mRNA and IL-10 mRNA was associated the increased plasma levels of TNF-alpha and IL-10 in the ischemic and reperfused myocardium compared with that in the sham group (P<0.01). Atorvastatin treatment prevented ischemia-reperfusion-induced up-regulation of both TNF-alpha and IL-10 mRNA, and improved left ventricular function (P<0.01). Our findings suggested that atorvastatin may attenuate MI/R and better recovery of left ventricle function following ischemia and reperfusion and IL-10 was not directly likely involved in this protective mechanism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19275881     DOI: 10.1016/j.bbrc.2009.03.019

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Atorvastatin reduces tissue damage in rat ovaries subjected to torsion and detorsion: biochemical and histopathologic evaluation.

Authors:  Elif Cadirci; Akgun Oral; Fehmi Odabasoglu; Cenk Kilic; Kagan Coskun; Zekai Halici; Halis Suleyman; Osman Nuri Keles; Bunyami Unal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-27       Impact factor: 3.000

2.  A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers.

Authors:  Rafael B R León-Cachón; Jorge A Ascacio-Martínez; María E Gamino-Peña; Ricardo M Cerda-Flores; Irene Meester; Hugo L Gallardo-Blanco; Magdalena Gómez-Silva; Everardo Piñeyro-Garza; Hugo A Barrera-Saldaña
Journal:  BMC Cancer       Date:  2016-02-08       Impact factor: 4.430

3.  Association of serum C1q/TNF-related protein-3 (CTRP-3) in patients with coronary artery disease.

Authors:  Shuhong Wang; Yuan Ling; Wei Liang; Linhui Shen
Journal:  BMC Cardiovasc Disord       Date:  2017-07-28       Impact factor: 2.298

4.  Early Effects of Atorvastatin on Vitamin D and Parathyroid Hormone Serum Levels Following Acute Myocardial Infarction.

Authors:  Batool Zarei; Maryam Mousavi; Saeideh Mehdizadeh; Hassan Mehrad-Majd; Maryam Zarif; Zahra Erfanian; Ali Moradi
Journal:  J Res Pharm Pract       Date:  2019 Jan-Mar

Review 5.  Anticoagulants and Statins As Pharmacological Agents in Free Flap Surgery: Current Rationale.

Authors:  Adnan Pršić; Elizabeth Kiwanuka; Stephanie A Caterson; Edward J Caterson
Journal:  Eplasty       Date:  2015-11-20

6.  Endothelial relaxation mechanisms and oxidative stress are restored by atorvastatin therapy in ovariectomized rats.

Authors:  Izabela Facco Caliman; Aline Zandonadi Lamas; Polyana Lima Meireles Dalpiaz; Ana Raquel Santos Medeiros; Glaucia Rodrigues Abreu; Suely Gomes Figueiredo; Lara Nascimento Gusmão; Tadeu Uggere Andrade; Nazaré Souza Bissoli
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.